Zobrazeno 1 - 10
of 385
pro vyhledávání: '"Hareth Nahi"'
Autor:
Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Fredrik Schjesvold, Nordic Myeloma Study Group
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/8e3d8502a05346dca5d9d8da6b8d16c6
Autor:
Katarina Uttervall, Love Tätting, Konstantinos Lemonakis, Mousa Majd, Jacob Crafoord, Mikael Olsson, Ulf‐Henrik Mellqvist, Markus Hansson, Hareth Nahi
Publikováno v:
Cancer Medicine, Vol 13, Iss 8, Pp n/a-n/a (2024)
Abstract Background Multiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug classes. Bispecific antib
Externí odkaz:
https://doaj.org/article/a9cfee7e086c4f91b55a890f5f1281fd
Autor:
Hareth Nahi, Gabriel Afram, Katarina Uttervall, Sandra Lockmer, Love Tätting, Gösta Gahrton, Muhammad Kashif, Evren Alici, Olga Stromberg, Monika Klimkowska, Johan Lund
Publikováno v:
Cancer Medicine, Vol 12, Iss 22, Pp 20736-20744 (2023)
Abstract Background The presence of minimal residual disease (MRD+) following autologous stem cell transplantation (ASCT) in multiple myeloma represents a poor prognostic factor for progression‐free survival (PFS) and overall survival (OS). Methods
Externí odkaz:
https://doaj.org/article/1903be302e0e4ca7b07df80c300622ad
Autor:
Michael T. Gundesen, Jon Thor Asmussen, Fredrik Schjesvold, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias S. Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Thomas Lund, Nordic Myeloma Study Group
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-5 (2023)
Externí odkaz:
https://doaj.org/article/c811f97abe5140df9599d414d2f0d468
Autor:
Manisha Bhutani, Alfred Garfall, Katarina Uttervall, Saad Z Usmani, Lionel Karlin, Lotfi Benboubker, Hareth Nahi, Jesús San Miguel, Danielle Trancucci, Keqin Qi, Tara Stephenson, Alfredo Perales-Puchalt, Katherine Chastain, Ajai Chari
Publikováno v:
HemaSphere, Vol 7, p e90600b0 (2023)
Externí odkaz:
https://doaj.org/article/57fb171e99b34443b7272faba575de36
Autor:
Raija Silvennoinen, Anu Partanen, Anders Waage, Valdas Pečeliūnas, Fredrik Schjesvold, Pekka Anttila, Katarina Uttervall, Marjaana Säily, Mervi Putkonen, Kristina Carlson, Einar Haukas, Marja Sankelo, Damian Szatkowski, Markus Hansson, Anu Marttila, Per Axelsson, Ronald Svensson, Birgitta Lauri, Maija Mikkola, Conny Karlsson, Johanna Abelsson, Erik Ahlstrand, Anu Sikiö, Monika Klimkowska, Reda Matuzeviciene, Mona Hoyseter Fenstad, Sorella Ilveskero, Hareth Nahi
Publikováno v:
HemaSphere, Vol 7, p e5534069 (2023)
Externí odkaz:
https://doaj.org/article/d72831d2759849ac8fefd808f7e030d6
Autor:
Michael Gundesen, Fredrik Schjesvold, Annette Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Elena Todorescu, Bo Amdi Jensen, Tobias S. Slørdahl, Jon Thor Asmussen, Hareth Nahi, Anders Waage, Niels Abildgaard, Thomas Lund
Publikováno v:
HemaSphere, Vol 7, p e014785b (2023)
Externí odkaz:
https://doaj.org/article/a108a6b70f8b4e33995dfbef1f87e357
Autor:
Roza Chaireti, Hareth Nahi
Publikováno v:
Hemato, Vol 3, Iss 3, Pp 518-526 (2022)
Multiple myeloma (MM) is a hematological malignancy characterized by a high risk for thrombotic episodes, mainly venous thromboembolism (VTE). This risk is accentuated by cancer treatments such as immunomodulatory drugs (IMiDs). Cancer-associated thr
Externí odkaz:
https://doaj.org/article/24ef88acbd064ada959fe76d215c0de0
Autor:
Göran Wålinder, Anna Genell, Gunnar Juliusson, Ronald Svensson, Antonio Izarra Santamaria, Jacob Crafoord, Kristina Carlson, Dorota Knut‐Bojanowska, Ljupco Veskovski, Birgitta Lauri, Johan Lund, Ingemar Turesson, Markus Hansson, Cecilie Hveding Blimark, Hareth Nahi
Publikováno v:
Cancer Reports, Vol 5, Iss 11, Pp n/a-n/a (2022)
Abstract Background We wanted to evaluate if health care for multiple myeloma (MM) patients is equal in different regions of Sweden. Aim To study differences in survival for MM depending on health care region and early use of modern treatment. Method
Externí odkaz:
https://doaj.org/article/ffd053207c734b989745cde79bf3b206
Autor:
Saad Z. Usmani, Hareth Nahi, Wojciech Legiec, Sebastian Grosicki, Vladimir Vorobyev, Ivan Spicka, Vania Hungria, Sibirina Korenkova, Nizar J. Bahlis, Max Flogegard, Joan Bladé, Philippe Moreau, Martin Kaiser, Shinsuke Iida, Jacob Laubach, Hila Magen, Michele Cavo, Cyrille Hulin, Darrell White, Valerio De Stefano, Kristen Lantz, Lisa O’Rourke, Christoph Heuck, Maria Delioukina, Xiang Qin, Ivo Nnane, Ming Qi, Maria-Victoria Mateos
Publikováno v:
Haematologica, Vol 107, Iss 10 (2022)
In the primary analysis of the phase III COLUMBA study, daratumumab by subcutaneous administration (DARA SC) demonstrated non-inferiority to intravenous administration (DARA IV) for relapsed or refractory multiple myeloma (RRMM). Here, we report the
Externí odkaz:
https://doaj.org/article/c2850abc3ea941e8857efb2bc647357e